The p140Cap adaptor protein in tumor progression

Research Fellowship duration 18 months

Paola Defilippi’s lab
Department of Molecular Biotechnology and Health Sciences
MBC1, Via Nizza 52, 10126 Torino, 011-6706434

Breast cancer (BC) is the most frequent form of tumor in women. Every year in Italy there are around 50,000 new cases of BC. Despite consolidated therapeutic protocols, approximately 15% of patients experience drug resistance. Overexpression of the receptor tyrosine kinase ErbB2 characterizes approximately 20% of human BC. ERbB2+ and Triple Negative subtypes undergo frequent relapses and drug resistance.

Defilippi’s lab will offer to the applicant all the conditions to carry out her/his work, with innovative techniques in a centre which benefit of the facilities required to carry on the proposed research, including fully equipped cell culture, microscope and animal facility.

List of publications at:

If interested, please write to for a meeting.